Literature DB >> 8895669

Enhanced expression of tissue inhibitors of metalloproteinases in human colorectal tumors.

M Murashige1, M Miyahara, N Shiraishi, T Saito, K Kohno, M Kobayashi.   

Abstract

Matrix metalloproteinases (MMP), such as 72 kDa type IV collagenase (MMP-2) and 92 kDa type IV collagenase (MMP-9), play an important role in tumor invasion and metastasis. Tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) are specific inhibitors of MMP. To evaluate the expression of TIMP-1, TIMP-2, MMP-2, and MMP-9 in human colorectal cancer, surgical specimens of primary colorectal cancer (66 cases) and liver metastases (10 cases) were examined by Northern and dot-blot hybridization. The levels of TIMP-1, MMP-2 and MMP-9 mRNA were significantly higher in primary colorectal cancers than in their adjacent normal tissues, and those of the mRNAs for all four genes were significantly higher in liver metastases than in normal colorectal tissues. Higher levels of TIMP-1 mRNA were positively correlated with lymph node metastasis and the five-year survival, and higher levels of TIMP-1 and TIMP-2 mRNA were positively correlated with the Dukes classification. Our findings suggest that the expression of TIMP-1 and TIMP-2 is closely correlated with the progression of human colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8895669     DOI: 10.1093/oxfordjournals.jjco.a023237

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  15 in total

1.  Matrix metalloproteinases in gastrointestinal cancer.

Authors:  P D Brown
Journal:  Gut       Date:  1998-08       Impact factor: 23.059

2.  Characterization of anti-TIMP-1 monoclonal antibodies for immunohistochemical localization in formalin-fixed, paraffin-embedded tissue.

Authors:  Irene Vejgaard Sorensen; Claus Fenger; Henrik Winther; Niels T Foged; Ulrik Lademann; Nils Brünner; Pernille A Usher
Journal:  J Histochem Cytochem       Date:  2006-03-03       Impact factor: 2.479

3.  Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer.

Authors:  O Schwandner; A Schlamp; R Broll; H P Bruch
Journal:  Int J Colorectal Dis       Date:  2006-08-02       Impact factor: 2.571

4.  Proteolysis in colorectal cancer.

Authors:  E A Garbett; M W Reed; N J Brown
Journal:  Mol Pathol       Date:  1999-06

5.  Evidence for tumor-host cooperation in regulating MMP-2 expression in human colon cancer.

Authors:  D L Ornstein; J MacNab; K H Cohn
Journal:  Clin Exp Metastasis       Date:  1999-05       Impact factor: 5.150

6.  Overexpression of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) in metastatic MDCK cells transformed by v-src.

Authors:  H Noritake; H Miyamori; C Goto; M Seiki; H Sato
Journal:  Clin Exp Metastasis       Date:  1999-03       Impact factor: 5.150

7.  Stromal matrix metalloproteinase 2 regulates collagen expression and promotes the outgrowth of experimental metastases.

Authors:  Andreia L Bates; Michael W Pickup; Miranda A Hallett; E Ashley Dozier; Stacy Thomas; Barbara Fingleton
Journal:  J Pathol       Date:  2015-01-05       Impact factor: 7.996

8.  Advanced colorectal carcinomas measuring 20 mm or less exhibit markedly higher invasiveness despite their size.

Authors:  Yasuhiro Kunii; Toshiki Kamano; Yuichi Tomiki; Shu Hirai; Shinji Kasamaki; Kazuhiro Sakamoto
Journal:  Dig Dis Sci       Date:  2004 Nov-Dec       Impact factor: 3.199

9.  Tissue inhibitor of metalloproteinase 1 expression associated with gene demethylation confers anoikis resistance in early phases of melanocyte malignant transformation.

Authors:  Tatiana I Ricca; Gangning Liang; Ana Paula M Suenaga; Sang W Han; Peter A Jones; Miriam G Jasiulionis
Journal:  Transl Oncol       Date:  2009-12       Impact factor: 4.243

10.  Expression of MMP-1, MMP-9 and TIMP-2 in prostate carcinoma and their influence on prognosis and survival.

Authors:  Ferhat Ozden; Caner Saygin; Didem Uzunaslan; Bulent Onal; Haydar Durak; Hilal Aki
Journal:  J Cancer Res Clin Oncol       Date:  2013-05-25       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.